Benzinga | Mar 31, 2021 07:59AM EDT

Wedbush Initiates Coverage On Chimerix with Outperform Rating, Announces Price Target of $14

Wedbush analyst David Nierengarten initiates coverage on Chimerix (NASDAQ:CMRX) with a Outperform rating and announces Price Target of $14.